Syntagon
Founded in 1998 in Södertälje, Sweden, Syntagon has more than two decades of experience in developing and manufacturing complex drug substances. In 2018, the company was acquired by Ardena, and in 2020 the legal entity name was updated to Ardena Södertälje—yet the core of who we are has always remained the same. Today, we are entering the next chapter of our journey as we proudly return to our original identity: Syntagon.
As an independent Swedish CDMO, we build on a long legacy of scientific excellence rooted in the strong life science tradition of Sweden. From world‑leading pharmaceutical innovation to pioneering chemical development, the region has fostered a culture of precision, responsibility, and deep scientific curiosity. This heritage continues to shape how we work and how we partner with customers around the world.
With a proven track record in API development, GMP manufacturing, and advanced analytical and purification technologies, Syntagon delivers fit‑for‑purpose solutions from early development to commercial supply. Our expertise spans small molecules, novel excipients, drug conjugates, and peptide conjugates, enabling us to support both innovative pipelines and established programs with the same level of scientific rigor.
What defines us is our commitment—to science, to quality, and to the people who rely on the medicines we help bring forward. We believe in collaboration, transparency, and building long‑term relationships founded on trust. At Syntagon, your molecule is met with the same dedication, care, and craftsmanship that have guided us since 1998.
Syntagon. Swedish science, global impact.